Stockscreener 앱 받기
0.9316
3.36%
-0.0324
시간 외 거래:
.98
0.0484
+5.20%
전일 마감가:
$0.964
열려 있는:
$0.99
하루 거래량:
2.41M
Relative Volume:
1.44
시가총액:
$89.26M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.4415
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
+10.90%
1개월 성능:
+29.39%
6개월 성능:
-1.94%
1년 성능:
-33.93%
1일 변동 폭
$0.8958
$1.035
1주일 범위
$0.82
$1.035
52주 변동 폭
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9316 | 80.49M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic Inc. Stock Analysis and ForecastHigh-profit stock alerts - Autocar Professional
What drives Immunic Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com
Is Immunic Inc. a good long term investmentFree Wealth Management Insights - jammulinksnews.com
What analysts say about Immunic Inc. stockDynamic growth stocks - jammulinksnews.com
IMUX’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
What makes Immunic Inc. stock price move sharplyValue Pick Scanner - Newser
How Immunic Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
Why Immunic Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser
Immunic board authorizes up to 35 million stock appreciation rights for employees By Investing.com - Investing.com South Africa
Immunic board authorizes up to 35 million stock appreciation rights for employees - Investing.com Australia
Immunic, Inc. Announces Proposed Public Offering - NewsBreak: Local News & Alerts
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - NewsBreak: Local News & Alerts
Immunic to Participate in Scientific and Industry Conferences in May - NewsBreak: Local News & Alerts
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial By Stocktwits - Investing.com India
Immunic, Inc. Announces Proposed Public Offering By Stocktwits - Investing.com India
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering By Stocktwits - Investing.com India
Immunic to Participate in Scientific and Industry Conferences in May By Stocktwits - Investing.com India
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Immunic to Participate in Investor, Scientific and Industry Conferences in June - MSN
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - NewsBreak: Local News & Alerts
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS By Stocktwits - Investing.com India
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis By Stocktwits - Investing.com India
Immunic to Participate in Investor, Scientific and Industry Conferences in June By Stocktwits - Investing.com India
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering By Stocktwits - Investing.com India
Immunic CEO discusses Phase 2 multiple sclerosis study successICYMI - Proactive Investors
Immunic reveals MS drug trial success - Proactive Investors
Immunic reports low disability worsening rates in MS drug trial By Investing.com - Investing.com Nigeria
Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium - Proactive financial news
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - Finansavisen
Immunic highlights MS treatment progression at BIO International Convention in Boston - Proactive Investors
Financial Metrics Check: Immunic Inc (IMUX)’s Ratios for Trailing Twelve Months - DWinneX
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages - Defense World
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted (NASDAQ:IMUX) - Seeking Alpha
Millennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic completes Phase 3 multiple sclerosis trial enrollmentICYMI - Proactive financial news
Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive financial news
Immunic at Jefferies Conference: Promising MS Drug Insights By Investing.com - Investing.com South Africa
Immunic at Jefferies Conference: Promising MS Drug Insights - Investing.com Australia
Small cap wrap: Midnight Sun Mining, Standard Uranium, Immunic, ReconAfrica... - Proactive Investors
Market movers: Tesla, Verint, PVH, Immunic... - Proactive financial news
Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):